Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors

"The Report Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:

Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA)
G-CSF & GM-CSF
Thrombopoietin & Thrombopoiesis Stimulating Agents
Interferon
Insulin
Coagulation Factors
Human Growth Hormone (hGH)
FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART)
Thrombolytics & Fibrinolytics
Enzyme Replacement Therapies

View Report @ https://www.marketresearchreports.biz/reports/167445/competitor-analysis-therapeutic-proteins-biosimilars-biobetters-biosuperiors-market-research-reports

Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.

With more than US$ 50 bln in sales, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.

Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/167445

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets. Competitor projects are listed in a tabular format providing Information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

Get Sample Copy Of This Report @
https://www.marketresearchreports.biz/sample/sample/167445

Table of Contents

1) Erythropoiesis Stimulating Agents (ESA)

First generation epoetins in regulated markets
Second generation epoetins in regulated markets
Epoetin biosimilars in regulated markets
Darbepoetin biosimilars in regulated markets
Next generation biologic Eythropoiesis Stimulating Agents (ESA) in regulated markets
Next generation small molecule Erythropoiesis Stimulating Agents
First generation EPO in less regulated markets (Latin America; Africa; Asia; RoW)
Darbepoietin biosimilars in less regulated markets
Next generation biologic ESAs in less regulated markets

2) G-CSF and GM-CSF

2012 Sales of Branded G-CSF Products in Regulated Markets
1st Generation Branded G-CSF Products in Regulated Markets
Biosimilar 1st Generation G-CSF Products in Regulated Markets
Next Generation Branded G-CSF Products in Regulated Markets
Biosimilar Next Generation G-CSF Products in Regulated Markets
1st Generation G-CSF Products in Non-Regulated Markets: India
1st Generation G-CSF Products in Non-Regulated Markets: China & Taiwan
1st Generation G-CSF Products in Non-Regulated Markets – Korea
1st Generation G-CSF Products in Non-Regulated Markets – Latin America
1st Generation G-CSF Products in Non-Regulated Markets: Other Territories
Next Generation G-CSF Products in Non-Regulated Markets
1st and Next Generation GM-CSF Products in Regulated Markets
1st and Next Generation GM-CSF Products in Non-Regulated Markets

3 ) Thrombopoiesis-Stimulating Agents (TPO; IL-11)

Thrombopoietin receptor (TPO-R) activators
Interleukin-11 (IL-11) receptor activators
Small molecule TPO-R Agonists
Corporate TPO/IL-11 Receptor Agonist Product Portfolios and R&D Pipelines

4 ) Interferon

a) INTERFERON alpha

Interferon alpha sales 2012 of branded products in regulated markets
1st generation Interferon alpha-2a in regulated markets
1st generation Interferon alpha-2a in non-regulated markets
Next generation Interferon alpha-2a in regulated markets
Next generation Interferon alpha-2a in non-regulated markets and biosimilars
1st generation Interferon alpha-2b in regulated markets
1st generation Interferon alpha-2b in non-regulated markets and biosimilars
Next generation Interferon alpha-2b in regulated markets
Next generation Interferon alpha-2b in non-regulated markets and biosimilars
Other Interferon alpha sub-types
Interferon alpha with not specified sub-type – 1/2
Purified natural human interferon alpha

b) Consensus INTERFERONs

c) INTERFERON beta

Interferon beta sales 2012 of branded products in regulated markets
1st generation Interferon beta-1a in regulated markets
1st generation Interferon beta-1a in non-regulated markets and biosimilars
1st generation Interferon beta-1b in regulated markets
1st generation Interferon beta-1b in non-regulated markets and biosimilars
1st generation Interferon beta with not disclosed sub-type
Next generation Interferon beta in regulated markets
Purified natural human interferon beta

d) INTERFERON gamma

e) Other INTERFERONs

5 ) Insulin

2012 Sales of branded recombinant human insulins in regulated markets
2012 Sales of branded short-acting recombinant human insulin analogs in regulated markets
2012 Sales of branded long-acting recombinant human insulin analogs in regulated markets
Rhu insulin (2nd generation) in regulated markets
Biosimilar rhu insulin (2nd generation) in regulated markets
Rhu insulin analogs (3rd generation) in regulated markets
Biosimilar rhu insulin analogs (3rd generation) in regulated markets
Ultra-long acting rhu insulin formulations and insulin analogs (4th generation)
Ultra-fast acting rhu insulin formulations and insulin analogs (4th generation)
Combinations of modern basal and prandial insulin & analogs (4th generation)
Combinations of insulin & GLP-1 agonist (4th generation)
Other combinations with insulin
Oral and Transbuccal Insulins (5th generation)
Inhaled and transdermal insulin
Novel approaches for insulin therapy
Rhu insulin (2nd generation) in non-regulated markets: India
Rhu insulin (2nd generation) in non-regulated markets: China
Rhu insulin (2nd generation) in non-regulated markets: Other Territories
Modern insulin analogs (3rd generation) in non-regulated markets

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.